Company news
Shanghai Medicilon, Inc. news in 2025
Shanghai Medicilon, Inc.'s news releases, calls and decks from 2025, newest first.
Announcement on Adjustment of Investment Types for Cash Management Using Idle Own Funds
November 21, 2025
Announcement on Shareholding Reduction Plan for Shareholder
November 19, 2025
Announcement on Expiration of Plan by Shareholder and Results of Shareholding Reduction
November 11, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
October 30, 2025
Announcement on the Completion of Non-Trade Stock Transfer under the 2025 Employee Stock Ownership Plan
October 28, 2025
Announcement on Resolutions of the 1st Holders' Meeting for 2025 Employee Stock Ownership Plan
September 24, 2025
Self-Inspection Report on the Trading of the Company's Stocks by Information Insiders of 2025 Restricted Stock Incentive Plan
September 15, 2025
Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2025 Restricted Stock Incentive Plan
September 8, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 5, 2025
Announcement on Litigation Involving Subsidiary
September 4, 2025
Special Report on Semi-annual Deposit, Management and Actual Use of Raised Funds in 2025
August 28, 2025
Announcement on Resolutions of the 5th Meeting of the 4th Board of Supervisors
August 8, 2025
Announcement on Implementation Results of Share Repurchase and Share Changes
July 14, 2025
Announcement on Abnormal Fluctuations in Stock Trading
July 9, 2025
Announcement on Progress in Repurchasing Shares through Call Auction
July 1, 2025
Announcement on Equity Change of Shareholders Reaching 1% and Results of Shareholding Reduction
May 30, 2025
Medicilon Passes FDA Inspection, Reinforcing Global R&D Excellence
May 29, 2025
Announcement on Repurchasing 1% Shares through Call Auction and Progress in Repurchasing Shares
May 28, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 13, 2025
Announcement on Share Reduction Plan for Shareholder
April 29, 2025
Announcement on Attending the Annual Collective Performance Briefing for Innovative Drug Industry on SSE STAR Market 2024 and Convening Q1 2025 Performance Briefing
April 25, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
April 22, 2025
Announcement on Provision for Asset Impairment and Write-off of Assets in 2024
April 21, 2025
Announcement on the Progress of Half Repurchase Period
April 11, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Postponing Some Investment Projects Financed by Raised Funds
January 24, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Electing Chairman, Chairman of the Board of Supervisors, and Members of Special Committees of the Board of Directors, and Appointing Senior Management Members and Securities Affairs Representative
January 13, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Restrictions Concerning Share Repurchase
January 9, 2025